MLICM
ZNTL icon

Metropolitan Life Insurance Company (MetLife)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,388
Closed -$53.4K – 2160
2024
Q1 		$53.4K Hold
3,388
– – ﹤0.01% 1372
2023
Q4 		$51.3K Hold
3,388
– – ﹤0.01% 1435
2023
Q3 		$68K Buy
3,388
+703
+26% +$17.8K ﹤0.01% 1228
2023
Q2 		$75.7K Buy
2,685
+163
+6% +$3.91K ﹤0.01% 1175
2023
Q1 		$43.4K Sell
2,522
-306
-11% -$6.2K ﹤0.01% 1469
2022
Q4 		$57K Hold
2,828
– – ﹤0.01% 1391
2022
Q3 		$61.3K Buy
2,828
+550
+24% +$15K ﹤0.01% 1321
2022
Q2 		$64K Hold
2,278
– – ﹤0.01% 1333
2022
Q1 		$105K Sell
2,278
-7,139
-76% -$385K ﹤0.01% 1161
2021
Q4 		$792K Hold
9,417
– – 0.01% 1131
2021
Q3 		$628K Buy
9,417
+908
+11% +$52.4K 0.01% 1298
2021
Q2 		$453K Buy
8,509
+230
+3% +$12.3K 0.01% 1582
2021
Q1 		$359K Hold
8,279
– – 0.01% 1619
2020
Q4 		$430K Buy
8,279
+4,774
+136% +$215K 0.01% 1456
2020
Q3 		$115K Hold
3,505
– – ﹤0.01% 2142
2020
Q2 		$168K Buy
+3,505
New +$134K ﹤0.01% 1921

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ZNTL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 3,388 shares — an estimated $53.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ZNTL in Q2 2020 and held it in 16 quarters. The position peaked at $792K in Q4 2021. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,388 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $53.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 16 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Zentalis Pharmaceuticals position peaked at $792K in Q4 2021.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.